Written question asked by Guto Bebb (Conservative) on Thursday, 17 September 2015, in the House of Commons. It was due for an answer on Wednesday, 14 October 2015 (named day). It was answered by George Freeman (Conservative) on Wednesday, 14 October 2015 on behalf of the Department of Health.
Nivolumab
- Question
-
To ask the Secretary of State for Health, what estimate he has made of the number of lung cancer patients who would benefit from the immunotherapy nivolumab; and if he will make a statement.
- Answer
-
NHS England has advised that it is not currently possible to estimate the numbers of patients in England who will be suitable for treatment, as the licence for nivolumab has been split into two distinct sub-groups (squamous and non-squamous non-small cell lung cancer) and the latter has yet to receive a marketing authorisation.
Secondary information
- Type
- Written question
- Reference
- 10597
- Session
- 2015-16
- Subjects
- Lung cancer Nivolumab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2016-07-05 20:08:13 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/10597
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/10597
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/10597